Who is sponsoring NCT01844999?

NCT01844999 is sponsored by Dana-Farber Cancer Institute.

What drugs are being tested in NCT01844999?

Interventions in NCT01844999: Personal Patient Profile - Prostate (P3P), Standard prostate cancer information websites.

What condition does NCT01844999 study?

NCT01844999 studies Prostate Cancer.

Is NCT01844999 still recruiting?

NCT01844999 is currently completed. Last updated 31 January 2018.

Last reviewed 2018-01-31 · How we verify

NCT01844999

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks

Completed NA Last updated 31 January 2018

What this trial tests

NA trial testing Personal Patient Profile - Prostate (P3P) in Prostate Cancer in 392 participants. Completed in 30 June 2017.

Timeline

1 August 2013

Primary endpoint
30 June 2016

30 June 2017

Quick facts

Lead sponsor	Dana-Farber Cancer Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	392
Start date	1 August 2013
Primary completion	30 June 2016
Estimated completion	30 June 2017
Sites	4 locations across United States

Drugs / interventions tested

Personal Patient Profile - Prostate (P3P)
Standard prostate cancer information websites

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Dana-Farber Cancer Institute

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine whether using the P3P website can increase decisional preparation and satisfaction, and decrease decisional conflict, in men deciding how to manage early stage prostate cancer.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Decision aids for people facing health treatment or screening decisions.
Stacey D, Lewis KB, Smith M, Carley M, et al · · 2024 · cited 203× · PMID 38284415 · DOI 10.1002/14651858.cd001431.pub6
Decision Support with the Personal Patient Profile-Prostate: A Multicenter Randomized Trial.
Berry DL, Hong F, Blonquist TM, Halpenny B, et al · · 2018 · cited 39× · PMID 28754540 · DOI 10.1016/j.juro.2017.07.076
Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial.
Berry DL, Hong F, Blonquist TM, Halpenny B, et al · · 2021 · cited 19× · PMID 33353864 · DOI 10.1016/j.urolonc.2020.11.038
Assigning value to preparation for prostate cancer decision making: a willingness to pay analysis.
Wilson LS, Blonquist TM, Hong F, Halpenny B, et al · · 2019 · cited 6× · PMID 30626400 · DOI 10.1186/s12911-018-0725-4
Concordance between influential adverse treatment outcomes and localized prostate cancer treatment decisions.
Pozzar RA, Xiong N, Hong F, Filson CP, et al · · 2022 · cited 2× · PMID 36002847 · DOI 10.1186/s12911-022-01972-w

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Dana-Farber Cancer Institute trials

Trials by the same sponsor.

NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01844999 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
Last refreshed: 31 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01844999.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing